MedInCell Stock Drops 3% but Still Up +74% Over the Year
The Montpellier-based biotech's stock fell by 2.78% to €26.62 at mid-session, in a Paris market weighed down by soaring long-term rates and a surge in Brent crude. Nevertheless, MedInCell's stock remains up nearly 74% over the year and has gained more than 8% over three months.
A Decline in a Difficult Session for Rate-Sensitive Stocks
The SBF 120 is down 0.69% at 6,012.97 points and the CAC 40 has lost 0.65% at 7,900.79 points during the session. Pressure comes from the bond markets: the yield on the 10-year U.S. Treasury has risen to 4.63%, a high since February 2025, while the 30-year Japanese bond hit a record around 4.20%. Brent crude is trading above $111 per barrel, fueling the scenario of sustained inflation and higher interest rates for longer. In this unfavorable environment for growth stocks and biotechs, MedInCell ranks low in the SBF 120, behind Ipsen, Nanobiotix, and Nexity. However, the decline remains moderate considering the recent trajectory: the target raised to €52 by Oddo on Friday pushed the stock to €28.14 at the end of the week, a level that was a high point for several months.
The Stock Maintains a Comfortable Technical Cushion Over Its Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Despite today's decline, MedInCell is trading above its three key moving averages. The price at €26.62 is 4.84% above the MM20 (€25.39) and 13.42% above the MM50 (€23.47), indicating that the medium-term momentum remains bullish. The RSI at 62 has exited the buying zone without entering oversold territory. The technical support identified at €21.68 leaves room before the trend is questioned. In the shorter term, the resistance at €28.72, corresponding to the peak on May 15, has not been breached. The biotech had crossed a graphical threshold before its R&D day on May 11, which supported the rally in the first half of the month. The next key date on the calendar is the general assembly in 2026, scheduled for September 10.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
